Vertex Pharmaceuticals Inc. (VRTX)
Last updated: 2026-10-20 09:30:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Summary
Vertex Pharmaceuticals Inc. (VRTX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $504.81, with a market capitalization of $126.66B and a P/E ratio of 28.88. Over the past 52 weeks, its price has ranged from $403.16 to $560.25. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$126.66B | |
$505.00 | |
$560.25 | |
$7.83 | |
$501.95 | |
46.00 | |
1.18M | |
28.88 | |
$560.25 | |
$403.16 | |
-- | |
2001-12-30 |
Vertex Pharmaceuticals Inc. (VRTX) Pre-Market Stock Price
Vertex Pharmaceuticals Inc. (VRTX) is trading at $504.81 in pre-market trading as of 2026-10-20 09:09:00, up 0.57% ($2.86) from the previous close of $501.95
Pre-market trading shows how investors are pricing VRTX before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Vertex Pharmaceuticals Inc. (VRTX) 7-Day Stock Price Change
Over the past seven days, Vertex Pharmaceuticals Inc. (VRTX) moved from $510.08 to $504.81, representing a decline of 1.03% ($5.27).
The stock traded between $484.08 and $517.68 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 1.53 million shares, up versus the previous seven-day period, indicating higher trading activity.
VRTX 52-Week Price Position
Position in Range: 64.7%
VRTX is currently trading at $504.81, placing it 64.7% of the way from its 52-week low of $403.16 to its 52-week high of $560.25. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Vertex Pharmaceuticals Inc. (VRTX)?
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is focused on diversifying its portfolio through Casgevy (gene-editing therapy for beta thalassemia and sickle-cell disease), Journavx (non-opioid pain drug for moderate-to-severe acute pain), and Palsonify (for acromegaly). Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases, cell therapies to deliver a functional cure for type 1 diabetes, povetacicept (for IgA nephropathy).
Vertex Pharmaceuticals Inc. Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 6400 |
| CEO | Reshma Kewalramani |
| Founded | 1989 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Vertex Pharmaceuticals Inc. (VRTX) Stock on MEXC
Eligible investors can buy real shares of Vertex Pharmaceuticals Inc. (VRTX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Vertex Pharmaceuticals Inc. (VRTX) stock price today?
2.Is VRTX stock going up or down today?
3.What is VRTX pre-market price?
4.What is VRTX after-hours price?
5.Is VRTX stock trading now?
6.Where does VRTX sit relative to its 52-week high and low?
7.What sector is Vertex Pharmaceuticals Inc. in?
8.What is Vertex Pharmaceuticals Inc.'s market capitalization and where is it listed?
9.How is VRTX valued in terms of P/E ratio and EPS?
10.Does Vertex Pharmaceuticals Inc. pay a dividend?
Explore More US Stocks
Search Stocks
VRTX Stock Calculator
Estimate the value between VRTX shares and USD.
VRTX Shares to USD
1.00 VRTX shares = 504.806 USD
Calculations are estimates based on the latest available price and are for reference only.


